The American Journal of Managed Care

Dr Jeff Stark: New Bimzelx Dose Offers Simplicity and Choice

On October 14, 2024, the FDA approved a 320-mg single dose of bimekizumab-bkzx (Bimzelx; UCB) in a 2-mL prefilled syringe and autoinjector; both forms are now commercially available in the US. To ...
Healio

FDA approves Bimzelx for treatment of moderate to severe plaque psoriasis

Please provide your email address to receive an email when new articles are posted on . Bimzelx (bimekizumab-bkzx) is the first and only interleukin 17A and 17F inhibitor approved in this indication.
Healio

Bimzelx 320 mg, 2 mL single-injection option now available for multiple indications

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The new Bimzelx administration and dosage is available ...
Nasdaq

UCB Announces U.S. FDA Approvals for BIMZELX® (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis

With three new indications, BIMZELX® (bimekizumab-bkzx) is the first and only IL-17A and IL-17F inhibitor approved in the U.S. for the treatment of four chronic immune-mediated inflammatory diseases ...
FiercePharma

UCB rapidly bolsters blockbuster potential for Bimzelx with 3 new FDA approvals

Less than a year after snagging its first FDA approval in psoriasis, UCB’s blockbuster hopeful Bimzelx has picked up three more indications to add to its growing resume of inflammatory disease ...
WRIC

UCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis Suppurativa

Approval is supported by data from the two Phase 3 studies, BE HEARD I and BE HEARD II, in which BIMZELX ® (bimekizumab-bkzx) improved the signs and symptoms of disease vs. placebo at Week 16, which ...
MarketWatch

BIMZELX(R) (bimekizumab-bkzx) Data in Hidradenitis Suppurativa Showed Improvements in Pain and Resolution of Draining Tunnels Sustained to Three Years

Only patients who entered the third year are included. (2-5) The approved dosing regimen is BIMZELX 320mg Q2W to Week 16 and then 320mg Q4W thereafter. (1) Results included patients receiving both Q2W ...
WOOD-TV

BIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-to-Severe Plaque Psoriasis

"A primary treatment goal for people living with psoriasis is durable, high rates of complete skin clearance. These five-year bimekizumab-bkzx results provide valuable evidence for clinical ...
Morningstar

BIMZELX® (bimekizumab-bkzx) Data in Moderate-to-Severe Plaque Psoriasis at EADV Showed Complete Skin Clearance Sustained Over Four Years

ATLANTA, Sept. 17, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced three- and four-year data from across the open-label extension (OLE) Phase 3 trials for BIMZELX® ...
Seeking Alpha

UCB Announces U.S. FDA Approvals for BIMZELX® (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis

ATLANTA, Sept. 23, 2024 /PRNewswire/ -- UCB, a global biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved BIMZELX ® (bimekizumab-bkzx) for the ...
Monthly Prescribing Reference

FDA Approves Bimzelx for Moderate to Severe Plaque Psoriasis

Credit: UCB. Bimzelx is expected to be available in November 2023. The Food and Drug Administration (FDA) has approved Bimzelx ® (bimekizumab-bkzx) for the treatment of moderate to severe plaque ...